SITC-NCI Computational Immuno-Oncology Webinar Series: Historical Perspective and Future Directions
In partnership with NCI’s Cancer MoonshotSM Initiative, the Society for Immunotherapy of Cancer (SITC) and the Big Data and Data Sharing Committee are launching the 2022 SITC-NCI Computational Immuno-Oncology Webinar Series. Dr. Eliezer M. Van Allen will kick off the series with his presentation, “Historical Perspective and Future Directions: Computational Science in Immuno-Oncology.” Discussion will be moderated by CBIIT’s Associate Director for Informatics and Data Science, Dr. Jill Barnholtz-Sloan. Attendees must log in or create a free SITC account to register.
Multiple molecular processes have been implicated in contributing to selective immunotherapy response across cancer types, although many open questions remain on how these processes interact and how this knowledge can be translated to clinical care. In this presentation, Dr. Van Allen will review key insights that have emerged regarding cancer immunogenomics, and examine open scientific questions at the interface of computational immuno-oncology and translation to clinical care, toward encouraging interdisciplinary strategies that address these issues and enhance treatment options for cancer patients.
The SITC-NCI Computational Immuno-Oncology Webinar Series consists of nine, hour-long courses featuring a moderator and faculty speaker to lead instruction. Topics will cover a host of computational challenges of analyzing and integrating diverse assay data across the spectrum of immuno-oncology. This series is intended for scientists early in their career and/or those who want to remain abreast of the latest technologies. These webinars were created to foster better communication concerning data science technologies and analyses between cancer immunotherapy researchers and clinicians to advance translational immunotherapy research.
Dr. Eliezer Van Allen is an associate professor of medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an associate member at the Broad Institute of MIT and Harvard. His research focuses on computational cancer genomics, the application of new technologies (such as massively parallel sequencing to precision cancer medicine), and resistance to targeted therapeutics.
Dr. Jill Barnholtz-Sloan is the associate director for the Informatics and Data Science Program at NCI’s Center for Biomedical Informatics and Information Technology and a senior investigator for NCI’s Division of Cancer Epidemiology and Genetics.